S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Forecast, Price & News

$9.14
+0.04 (+0.44%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.92
$9.24
50-Day Range
$7.66
$9.50
52-Week Range
$7.36
$15.24
Volume
811,391 shs
Average Volume
776,034 shs
Market Capitalization
$738.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.60

Anavex Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
366.1% Upside
$42.60 Price Target
Short Interest
Bearish
19.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.77mentions of Anavex Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

582nd out of 983 stocks

Biological Products, Except Diagnostic Industry

90th out of 164 stocks


AVXL stock logo

About Anavex Life Sciences (NASDAQ:AVXL) Stock

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
The Latest Analyst Ratings for Anavex Life Sciences
Analyst Ratings for Anavex Life Sciences
What's Going On With Anavex Life Sciences Shares Today?
See More Headlines

AVXL Price History

AVXL Company Calendar

Last Earnings
5/09/2023
Today
6/03/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.60
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+366.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-47,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.80 per share

Miscellaneous

Free Float
71,461,000
Market Cap
$738.86 million
Optionable
Optionable
Beta
0.73

Key Executives

  • Christopher U. Missling
    Chairman, President, CEO & Secretary
  • Stephan Toutain
    Chief Operating Officer
  • Sandra Boenisch
    Chief Financial Officer & Treasurer
  • Walter E. Kaufmann
    Chief Scientific Officer
  • Edward R. Hammond
    Chief Medical Officer













AVXL Stock - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price forecast for 2023?

4 analysts have issued 1 year target prices for Anavex Life Sciences' stock. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they expect the company's stock price to reach $42.60 in the next twelve months. This suggests a possible upside of 366.1% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2023?

Anavex Life Sciences' stock was trading at $9.26 at the beginning of 2023. Since then, AVXL shares have decreased by 1.3% and is now trading at $9.14.
View the best growth stocks for 2023 here
.

Are investors shorting Anavex Life Sciences?

Anavex Life Sciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 15,900,000 shares, an increase of 10.6% from the April 30th total of 14,380,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 15.9 days.
View Anavex Life Sciences' Short Interest
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.21%), State Street Corp (7.02%), Geode Capital Management LLC (1.80%), Charles Schwab Investment Management Inc. (0.70%), Nwam LLC (0.69%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $9.14.

How much money does Anavex Life Sciences make?

Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $738.86 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.

This page (NASDAQ:AVXL) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -